Two funded biological drugs bring hope to up to 25,000 patients with poorly controlled COPD in Spain

The financing of two biologics for COPD opens up new options for thousands of patients in Spain and reinforces the call not to normalize symptoms.

Add DEMÓCRATA to Google

Ask FREN

Published

4 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 17 institutos

  • PP31,5 %
  • PSOE27,2 %
  • Vox18,9 %
  • Frente Amplio6,4 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

Pulmonologist Andrea Yordi has emphasized that the recent funding of the biological treatments dupilumab and mepolizumab "opens a path of hope" for between 20,000 and 25,000 people in Spain with chronic obstructive pulmonary disease (COPD) who present type 2 inflammation and poor disease control.

Coinciding with World COPD Day, which is observed this Wednesday, the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) has highlighted progress in addressing this condition. Yordi has stressed therapeutic innovations and the need for increasingly personalized treatment, noting that these biologics offer an option for patients who until now lacked effective alternatives.

As she explained, these medications, which are administered in hospitals and have been funded since July, work by blocking type 2 inflammation signals, caused by an increase in a type of white blood cell called an eosinophil, present in around 20 percent of patients with COPD.

Funding has been authorized for patients who meet three specific criteria. In addition to having type 2 inflammation, they must have followed triple inhaled therapy for six months and, despite this, continue to have poor disease control, with at least two mild exacerbations or one severe one in the last year.

Clinical trials have shown that these biologics manage to reduce by up to 34 percent moderate or severe exacerbations and by around one third visits to emergency department services. They have also evidenced improvements in patients’ lung function and quality of life, as the specialist has detailed.

However, she has recalled that the clinical studies had a duration of between one and two years and that the use of these drugs in real-world practice is still recent, so their long-term impact is not yet known with exactness, although it is expected to be favorable thanks to the reduction in exacerbations.

The biological treatment must be administered together with the usual bronchodilators, without replacing them, and it presents mild side effects and a safety profile considered good. In several hospitals they are already prescribing it: it starts with administration at the center itself and, later, the patient can pick it up at the hospital pharmacy and inject it themselves at home.

Yordi, a member of the coordination team for the SEPAR Year of the Airway 2026-2027, has encouraged people with COPD who continue to suffer flare-ups despite correctly continuing with their treatment to consult their doctor to assess whether they meet the criteria for accessing these biological therapies.

DO NOT NORMALIZE THE SYMPTOMS

The pulmonologist Patricia Sobradillo, coordinator of the SEPAR Year of the Airway 2026-2027, has reminded that COPD is a "very common" disease, affecting 12 percent of the Spanish population. It is defined by a persistent and irreversible narrowing of the bronchi, whose main cause is tobacco consumption, although environmental or workplace exposures and certain genetic factors also play a role.

Among the most common signs are cough, with or without phlegm, and the sensation of lack of air during efforts, which ends up appearing with activities that are increasingly less intense. Sobradillo has insisted that "it is not normal" to live with these symptoms and has asked those who suffer from them to go to their doctor for an assessment.

She has pointed out that the incidence has been stabilizing in recent years, but has warned that it is increasing among women. One of the major problems is that 75 percent of those affected do not know that they have the disease, do not have a diagnosis and, consequently, do not receive treatment.

As she indicated, this high underdiagnosis is due to "the sum of many factors," among which the limited social knowledge of COPD and the difficulties in generalizing the key diagnostic test, spirometry, stand out.

In addition, she has warned that underdiagnosis is still greater in women, where it is around 80 percent, in part because they go to appointments less often. Although it is the same condition, its clinical expression differs depending on sex: they suffer more exacerbations but are hospitalized less, they experience a greater sensation of choking, more anxiety, depression and osteoporosis, and less chronic bronchitis. Even so, the therapeutic approach is the same.

The gateway to the healthcare system is Primary Care, from where patients are referred to pulmonology services. At this point, Sobradillo has warned that there are not enough specialists to attend to all patients, a problem that could worsen if the prevalence of COPD increases with the aging of the population.

IMPACT OF EXACERBATIONS

The specialist has also analyzed the effect of exacerbations, episodes of sudden and severe worsening of symptoms, generally related to infections. For this reason, she has emphasized the need to promote vaccination in the general population and, in particular, in those who suffer from respiratory diseases.

She explained that the consequences of these decompensations, which require going to Primary Care or even being admitted to the hospital, can last up to six months. In addition, an exacerbation increases the likelihood of suffering new episodes, generating a "spiral".

It is estimated that each year around 70,000 hospital discharges and 90,000 Emergency Department visits are recorded due to acute exacerbations of COPD, with an average stay of eight days. All of this has a notable impact on the patient’s daily life and on that of their caregivers.

The annual direct cost of COPD is around 1,000 million euros and, if indirect costs are added, the figure rises to about 3,000 million. In addition, it is estimated that each hospital admission for COPD involves an average expense of 4,800 euros.

For this reason, Sobradillo has insisted on the urgency of paying more attention to COPD, preventing its symptoms from being normalized, and strengthening prevention and treatment strategies. All of this is framed within the SEPAR Year of the Airway 2026-2027, which the scientific society dedicates to asthma, COPD, and bronchiectasis under the slogan "Listen to your breathing".